The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison between the outcome of metastatic RCC patients treated with sunitinib as part of clinical trials and matched nonparticipants receiving sutent as standard therapy.
Raanan Berger
No relevant relationships to disclose
Maya Ish-Shalom
No relevant relationships to disclose
Natalie Maimon
No relevant relationships to disclose
Maya Gottfried
No relevant relationships to disclose
Roberto Pili
No relevant relationships to disclose
Hans J. Hammers
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Victoria J. Sinibaldi
No relevant relationships to disclose
Ben Boursi
No relevant relationships to disclose
Rony Weitzen
No relevant relationships to disclose
Henry Hayat
No relevant relationships to disclose
Avivit Peer
No relevant relationships to disclose
Avivit Neumann
No relevant relationships to disclose
Svetlana Kovel
No relevant relationships to disclose
Avishay Sella
No relevant relationships to disclose
Wilmosh Mermershtain
No relevant relationships to disclose
Keren Rouvinov
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose
Daniel Keizman
No relevant relationships to disclose